The U.S. Federal Aviation Administration (FAA) has concluded its investigation into the anomaly during SpaceX's 12th Starship test flight. The agency has accepted SpaceX's proposed corrective actions, clearing the way for the 13th test flight, which SpaceX plans to conduct as early as the 16th. In separate news, Dizhu Pharma announced a licensing agreement with AstraZeneca UK Limited, granting AstraZeneca exclusive global rights to develop and commercialize Shuwozhe®. Dizhu Pharma will receive an upfront payment of $600 million, with potential milestone payments totaling up to $900 million and tiered royalties on global sales. AI
RANK_REASON The FAA's clearance for a Starship test flight is a significant regulatory event for a major aerospace project, alongside a substantial drug licensing deal. [lever_c_demoted from significant: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
